Navigation Links
OPKO Health Announces Changes to Board of Directors
Date:1/25/2008

ercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase III clinical trial for bevasiranib, may not be successful, that the Phase III clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contacts: Media:

Corporate: GendeLLindheim BioCom Partners

Steven D. Rubin Barbara Lindheim

305 575-6000 212 918-4650


'/>"/>
SOURCE OPKO Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., , ATLANTA, Dec. 2 In res...he U.S. military, FamilyLife, a non-profit ministr...will present its Weekend to Remember® marri...ry couples in Atlanta from Dec. 11 - 13 at the Gra...NE). Weekend to Remember is a marriage getaway ...
(Date:12/2/2009)..., , Ad in Today,s Washington Post H...swire-USNewswire/ -- If the Catholic bishops ha...tive measures we take for granted may be under thr...t to bear on the debate over healthcare reform has...shington Post warns of the likely impact if that ...
(Date:12/2/2009)..., , KANSAS CITY, Mo., Dec. 2 /PRN...mployers with a comprehensive, practical view on p...Congress. ,, (Logo: http://www.newscom.com/c...yers, there is good, bad, and ugly in the legislat...ttorneys in Lockton Benefit Group,s Compliance Se...
(Date:12/2/2009)...tudy finds myriad microbes in tobacco, but risk is...y News) -- New research provides evidence that th...ing bacteria that cause respiratory disease. , ... out, the authors of the new study aren,t sure wha...bacteria is nothing new: Microbes surround us ever...
(Date:12/2/2009)... Durham, NCDecember 2, 2009Ninety-six percent of l...dy on gender-based distrust indicated a strong gen...ver, this general distrust towards men did not pre...or romantic relationship. Furthermore, the union w...trusting," despite their prior assertions of distr...
Breaking Medicine News(10 mins):Health News:FamilyLife Supports Military Marriages in Atlanta 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2Health News:Lockton Outlines Implications of Proposed Health Reform Plans 2Health News:Smokers Inhaling Germs With Each Cigarette 2
... cancer cells are able to spread to distant parts ...ells spread to the target site via the blood or th...re. It has now emerged that certain chemicals ...rs from the Cornell University's Weill Medical Col...
... speech can be processed much faster by the brain ...cochlear implant is carried out at an early age//,...ts. About 36 profoundly deaf children aged between...at seeing to what extent children with the implant...
...ducted to determine the effectiveness of 27 differ...evels; sunflower seeds and pistachio nuts have bee... of high levels of phytosterol (plant chemicals wh...tion. On analysis, sesame seeds and wheat ge...
...m passive bystanders to good Samaritans in situati...ers report//. Occasions when a crowd of people...l known. Psychologists call it the "bystander effe... can become knights in shining armour. An exp...
...om color blindness due to X-chromosome variations,...olors but have an increased sensitivity to differe... be differentiated by normal persons. The results ...olors are differentiated by the eyes by cone photo...
...University of Birmingham tested the 'Bambach Saddl..., and have concluded that it serves to relieve bac...ds, was found to keep the spine in its natural 'S'... given a task to perform. This was based on the po...
Other Medicine News:Health News:Initial Steps In Spread Of Cancer Identified 2Health News:Early Cochlear Implants Prove To Be Effective 2Health News:Colorblind Individuals have expanded color vision 2Health News:New Chair Invented To Relieve Backache 2
(Date:12/2/2009)...LAGE, Nev., Dec. 2 PDL B...ced that it has established the per share amount o...vidend as $1.67 per share. The dividend will be pa...any,s stock as of the December 1, 2009 record date...per share amount of the dividend at $1.67 per shar...
(Date:12/2/2009)...EJO, Calif., Dec. 2 Clar...and services resource for pathologists, oncologist... a Chief Financial Officer transition plan that ca...riguez to become its Senior Vice President and Chi...J. Land, age 64, the current Senior Vice President...
(Date:12/2/2009)...ST HANOVER, N.J., Dec. 2 Novartis ...eaking presentation on Tasigna® (nilotinib) 2...ia, demonstrate the strength of the company,s hema.... ,, The new data, at the 51st American Societ...n, highlight the company,s current therapies and i...
Breaking Medicine Technology:PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 2PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 3Clarient Announces CFO Transition Plan 2Clarient Announces CFO Transition Plan 3Clarient Announces CFO Transition Plan 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Pandesa ShareVault Enables Secure Real time Due Diligence for Biopharmaceutical Partnering 14096 1Pandesa ShareVault Enables Secure Real time Due Diligence for Biopharmaceutical Partnering 14096 2Pandesa ShareVault Enables Secure Real time Due Diligence for Biopharmaceutical Partnering 14096 3Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 1Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 2Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 3Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 4Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 5Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 6Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 7Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 8Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 1Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 2Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 3
...2/Insulin Significantly Lowered Blood Glucose with...ions,Phase 2 Trial Expected to Begin upon Ethics A... 2008, MELBOURNE, Australia, Aug. 8 ..., AIM: PSG, OTCQX: PPGNY) today,announced the succ...n,trial. The positive results of the trial demonst...
... Continued Investment in Clinical Development of T...uticals, Inc. (Nasdaq: TPPH ) announced today fin...7, 2007. The net loss for the second quarter of 2...pares to a net loss for the second quarter of 2006...the net loss for the second,quarter of 2007 and 20...
Other Medicine Technology:Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 2Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 3Tapestry Reports Second Quarter 2007 Results 2Tapestry Reports Second Quarter 2007 Results 3Tapestry Reports Second Quarter 2007 Results 4Tapestry Reports Second Quarter 2007 Results 5Tapestry Reports Second Quarter 2007 Results 6
OneTouch® UltraSoft® Lancets
OneTouch® Fine Point™ Lancets
Microtainer Quikheel Lancet
HEMOCHRON Jr. Signature+ Microcoagulation System
Medicine Products: